Newsfeeds - Spark Newswire

1 minute read

PhaseBio Says Antiplatelet Candidate Achieved Primary Reversal Endpoint In Late-Stage Study

Today, 5:43 PM

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects…

AZN

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline

Today, 5:43 PM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

1 minute read

PhaseBio Pharmaceuticals Q3 EPS $(0.66) Up From $(0.86) YoY, Sales $335.00K

By Benzinga Newsdesk

Today, 5:43 PM

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.66) per share. This is a 23.26 percent increase over losses of $(0.86) per share from the same period last year. The company reported $335.00

PHAS

1 minute read

PhaseBio’s Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study

By Vandana Singh

Today, 5:43 PM

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years…

AZN

3 minute read

PhaseBio Announces Topline Results From Phase 2b Trial For Bentracimab; Co. Reports ‘Trial achieved primary reversal endpoint in healthy, older volunteers’

By Benzinga Newsdesk

Today, 5:43 PM

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced topline data from

PHAS

1 minute read

Legal
News

PhaseBio Pharmaceuticals Receives Notice Of Allowance For US Patent Titled ‘METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS’

By Benzinga Newsdesk

Today, 5:43 PM

https://twitter.com/PatentGrants/status/1453779201446715411

PHAS

1 minute read

PhaseBio Pharmaceuticals Q2 EPS $(0.06) Up From $(0.98) YoY

By Steve Krause

Today, 5:43 PM

PhaseBio Pharmaceuticals (NASDAQ: PHAS) reported quarterly losses of $(0.06) per share.

PHAS

5 minute read

PhaseBio Pharmaceuticals Announces First 143 Patients Enrolled In REVERSE-IT Global Phase 3 Trial

By Bill Haddad

Today, 5:43 PM

First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive

PHAS

1 minute read

Legal
News

PhaseBio Pharmaceuticals Granted U.S. Patent Titled ‘Methods and compositions for treating cystic fibrosis’

By Benzinga Newsdesk

Today, 5:43 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6514&f=G&l=50&d=PTXT&p=131&S1=20210706&OS=20210706&RS=20210706

PHAS

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 5:43 PM

Gainers

ADMP